DNA Repair Drugs Market SWOT Analysis, Segmentation, Applications & Emerging Audience Till 2026

DNA Repair Drugs .jpg

DNA can be damaged due to endogenous factors (oxidation) or exogenous factors (UV radiations or viruses), but our cell can identify and repair the damage. However, when the repairing mechanism of the cell fails, it leads to dysfunctionality or mutations in the DNA of the cell. It can also lead to abnormal growth of cells, i.e., cancer. Such irreparable damage can be treated with DNA repair drugs such as poly ADP-ribose polymerase inhibitors (PARP). PARP blocks the activity of ADP-ribose polymerase proteins, thus preventing the replication of cancer cells.

Global DNA Repair Drugs Market Drivers

Increasing collaboration and acquisition activities are expected to boost the global DNA repair drugs market growth. For instance, in January 2017, Merck KGaA entered into a licensed agreement with Vertex Pharmaceuticals Inc., for four research developments on approaches to cancer. The reason for the partnership was to strengthen Merck’s area of DNA damage response and immuno-oncology. Furthermore, in February 2016, Onxeo, an orphan oncology therapeutics company, acquired DNA Therapeutics, a biopharmaceutical company for its DNA repairing technology for treatment of cancer. This technology consists of a signal interfering DNA molecule (siDNA), and Onxeo S.A. intends to develop this technology as a potential treatment option for cancer. Such partnerships are expected to propel the global DNA repair drugs market growth.

Global DNA Repair Drugs Market Regional Analysis

North America is expected to hold a dominant position in the global DNA repair drugs market. Factors such as increasing research and development activities are expected to have an influence on the North America’s DNA repair drugs market growth. For instance, in 2017, Harvard Medical School and University of South Wales conducted a study on DNA repair drugs for treatment of radiation damage that causes cancer. They have discovered the mechanism that weakens the system of our cell’s capability to repair the damages. They developed a drug, which was tested on mice and the mice were successfully able to retrieve the cell functions. The successful development of such researches is expected to propel the global DNA repair drug market growth.

Global DNA Repair Drugs Market Restraints

Failure of drugs in late stages of clinical trials has hampered the global DNA repair drugs market growth. For instance, in April 2017, Veliparib, a product by AbbVie was withdrawn from both the clinical trial studies. One of the clinical trial study involved the drug’s efficacy on breast cancer and other for lung cancer. Veliparib was treated with a combination of chemotherapy for both, lung and breast cancer treatment. Both of the trials were withdrawn at its third phase. Such failures may hinder the global DNA repair drugs market growth.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2617

Global DNA Repair Drugs Market Key Players

Some of the major players operating in the global DNA repair drugs market include 4SC AG, Artios Pharma, Johnson & Johnson Service Inc., GlaxoSmithKline plc, Genentech, Inc., Sierra Oncology Inc., AstraZeneca, Karyopharm Therapeutics, Jiangsu Hengrui Medicine Co., Ltd., and Merck KGaA.

Global DNA Repair Drugs Market Taxonomy

The global DNA repair drugs market is segmented on the basis of drug, application, distribution channels, and regions.

By Drug

Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
Others

By Application

Ovarian cancer
Fallopian tube cancer
Peritoneal cancer
Breast cancer
Gastric cancer

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Region

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments

Post a Comment

Popular posts from this blog

Why the Cold Pain Therapy is a Growing Payer Opportunity?

Image
Cold pain therapy is a therapeutic application of cold, used in the treatment of acute soft tissue injuries and to reduce the pain in post-operative condition in orthopedic surgeries, treatment of benign and malignant lesions, and in pain management. Cryotherapy can be applied topically (on the skin surface), surgically or percutaneously. This can also be used to treat various skin conditions such as oral mucositis and tumors in the liver, kidney, bones, breasts and lungs, skin tumors, skin tags, pre-cancerous skin moles, and injuries. Cryosurgery procedure involves use of extreme cold, produced with help of liquid nitrogen (or argon gas) to destroy abnormal tissues. According to the National Cancer Institute (NCI), cryosurgery is used for treatment of several types of cancers and some non-cancerous conditions. It is reported to be effective for treatment in early stage skin cancer, retinoblastoma, actinic keratosis, and cervical intraepithelial neoplasia. Accord...
Read more

Ursodeoxycholic Acid Market Shows Boosted Growth Rate 2018-2026 Estimated by Global Top Players

Image
Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent the progression of cystic fibrosis-related liver disorder. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover it can improve long-term survival in patients with primary biliary cirrhosis. Significant improvement in liver health can be achieved during UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases. The global ursodeoxycholic acid market size was valued at US$ 346.2 million in 2017, and is expected to witn...
Read more

Booms and Busts in Anatomic Pathology Market; Dynamics Trends Over The Time Discussed 2018-2026

Image
Anatomic pathology involves direct visualization of human tissue as gross examination as well as under a microscope for proper diagnosis of the disease or a pathological condition. Subtypes of anatomic pathology include surgical pathology, oral and maxillofacial pathology, cytopathology, molecular pathology, and forensic pathology. Procedures performed in anatomic pathology include gross examination, histopathology, immunohistochemistry, in situ hybridization, cryopathology, tissue cytogenetics, and others. Standard approach in anatomical pathology is microscopic examination of tissue samples with the help of one or more stains. Manufacturers have developed stains to identify and classify microorganisms in biopsy of tissue samples or excisional specimens. Various gram stains and acid-fast stains have applications in detection of bacteria and mycobacteria in tissue samples. Commercially available products include tissue processing systems, microtomes, cryostats, ...
Read more